CARDIFF ONCOLOGY, INC. Development Stage Entities, Equity Issuance, Per Share Amount (Deprecated 2015-01-31)
CARDIFF ONCOLOGY, INC. (CRDF) reported Development Stage Entities, Equity Issuance, Per Share Amount (Deprecated 2015-01-31) of $0.003 for the 12-month period ending 2003-01-31, per its 10-K filed 2014-03-17.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EquityIssuancePerShareAmount · last filed 2014-03-17
- CARDIFF ONCOLOGY, INC. development stage entities, equity issuance, per share amount (deprecated 2015-01-31) for fiscal 2003 was $0.00.
| Period end | Development Stage Entities, Equity Issuance, Per Share Amount (Deprecated 2015-01-31) 12 month |
|---|---|
| 2003-01-31 | $0.00 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |